Single-agent responses varied across cancer cell lines. At 10 μM BV6, MTT viability decreased significantly in several lines, while Amo-1, KMS.11 and HeLa showed no significant decrease at 48 h. MTT viability is not a direct apoptosis measurement. In a separate human SGBS adipocyte model, HOIP loss increased susceptibility to TNF plus 500 nM BV6, with protection by a pan-caspase inhibitor. The adipocyte experiment used Selleck BV6; the paper’s separate Adooq A14231 methods entry does not establish Adooq use for that result. [2,3]
Relief of XIAP-mediated caspase inhibition
Biochemical assay · Purified recombinant caspase-3 or caspase-7 (300 pM) with XIAP BIR2–BIR3 (10 nM) [1]
BV6 restored caspase activity in a concentration-dependent but partial manner; BVE6, described as the nonbinding enantiomer, did not show comparable restoration. This is an activity-rescue assay, not a BV6 binding-affinity measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- BV6 or BVE6: 0.02, 0.07, 0.20, 0.61, 1.83, 5.49, 16.5, 49.4, 148 and 444 μM, as printed in Figure 5A–B.
- Exposure duration
- 1 h preincubation at room temperature; kinetic read for 30 min at 37°C after substrate addition.
- Method
- Fluorogenic ac-DEVD-AFC cleavage (25 μM substrate); enzyme-only control assigned 100% and enzyme plus XIAP without antagonist assigned 0%.
- Vehicle
- DMSO; matched replacement when compounds were absent.
Methods and source locations
Compound reported in the paper: BV-6; Compound label in the paper: BV6
Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.
Figure 5A–B; Experimental Procedures—Caspase Activity Assay; Results—XIAP discussion preceding Figure 5
Caspase-3 and caspase-7 activity after XIAP inhibition: Fluorogenic enzyme assay; no exact bar heights extracted. — Figure 5A–B; Caspase Activity Assay
cIAP protein loss and NIK accumulation in cancer cells
Cell-based study · KMS12.BM, MMI.s, RPMI, KMS.11, HT29 and HT1080 human cancer cells [2]
BV6 decreased cIAP1 and/or cIAP2 abundance and increased NIK. Increased p100 processing to p52 was reported principally in KMS12.BM, HT29 and HT1080. The patterns varied across cells; these blots do not directly measure BV6 binding or prove proteasomal dependence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 0.016, 0.08, 0.4, 2 and 10 μM BV6.
- Exposure duration
- 8 h
- Method
- Western blotting with tubulin loading control.
- Reported limits
- Vehicle for the Figure 1 zero-dose lanes and biological replicate count are not specified in its caption; no densitometric effect size reported there.
Methods and source locations
Compound reported in the paper: BV-6; Compound label in the paper: BV6
Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.
Figure 1 image/caption; Results—BV6 induces IAPs degradation and NIK accumulation; Chemicals and Western blotting methods
cIAP1/cIAP2, NIK and p100/p52 protein patterns: Western blot; qualitative interpretation only. — Figure 1; corresponding Results paragraph
Cell-dependent single-agent viability response
Cell-based study · Eleven human cancer cell lines: KMS12.BM, L363, MMI.s, OPM2, RPMI, Amo-1, KMS.11, HT29, HT1080, HeLa and Jurkat [2]
At 10 μM, statistically significant MTT viability decreases were reported at 24 h in L363, MMI.s, HT1080 and Jurkat, and at 48 h in all tested lines except Amo-1, KMS.11 and HeLa. The MTT endpoint alone does not identify apoptosis.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM BV6
- Exposure duration
- 24 or 48 h
- Method
- MTT viability assay; Student’s t-test in shared Statistical analysis.
- Vehicle
- PBS:methanol (1:1), reported BV6 vehicle control.
Methods and source locations
Compound reported in the paper: BV-6; Compound label in the paper: BV6
Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.
Figure 2 image/caption; Results—BV6 induces cell death in different human cell lines; Cell death assay and Statistical analysis
MTT viability at 24 h: MTT, triplicate treatments. — Figure 2; Results—BV6 induces cell death in different human cell lines
MTT viability at 48 h: MTT; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 defined in shared methods; no per-bar values inferred. — Figure 2; corresponding Results paragraph
HOIP deficiency increases adipocyte susceptibility to TNF plus BV6
Cell-based study · Differentiated human SGBS adipocytes: empty-vector control versus HOIP-knockout clone 1.1.1 [3]
HOIP-deficient adipocytes were more susceptible to TNF plus BV6 than empty-vector cells. In the inhibitor comparison, zVAD prevented death without an additional benefit from 7-O-Cl-Nec-1, consistent with caspase-dependent death in this context. This does not demonstrate a BV6 effect on obesity in animals.
Literature-Reported Treatment Conditions
- Treatment concentration
- 500 nM BV6; increasing TNF in Figure 5I; TNF 0.1 ng/mL in Figure 5J.
- Exposure duration
- 24 h
- Method
- CellTiter-Glo ATP-based viability assay.
- Vehicle
- DMSO control; viability in Figure 5J is expressed relative to DMSO.
- Co-treatment
- TNF; Figure 5J additionally compares zVAD-fmk (20 μM), 7-O-Cl-Nec-1 (10 μM), or both.
Methods and source locations
Compound reported in the paper: BV-6; Compound label in the paper: BV6
Evidence concerns the named BV6 reagent in the reported model; it does not validate an Adooq lot or establish clinical efficacy.
Figure 5I–J image/caption; human adipocyte Results; Methods—SGBS cell culture and Human and mouse pre- and adipocytes
Viability under TNF plus BV6: CellTiter-Glo; n = 3; means ± SD. — Figure 5I image/caption; associated Results
Effect of cell-death inhibitors on TNF/BV6 viability: CellTiter-Glo; n = 5; means ± SD; qualitative result, no curve-derived percentages. — Figure 5J image/caption; associated Results; human adipocyte viability methods